<?xml version="1.0" encoding="utf8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">JHOR</journal-id>
      <journal-title-group>
        <journal-title>Journal of Hematology and Oncology Research</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2372-6601</issn>
      <publisher>
        <publisher-name>Open Access Pub</publisher-name>
        <publisher-loc>United States</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">JHOR-22-4061</article-id>
      <article-id pub-id-type="doi">10.14302/issn.2372-6601.jhor-22-4061</article-id>
      <article-categories>
        <subj-group>
          <subject>research-article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evolution of the Solid Human Tumor Cells Properties in Various Experimental Systems in Vitro </article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Anna</surname>
            <given-names>B. Danilova</given-names>
          </name>
          <xref ref-type="aff" rid="idm1841801668">1</xref>
          <xref ref-type="aff" rid="idm1841703228">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Natalia</surname>
            <given-names>A. Efremova</given-names>
          </name>
          <xref ref-type="aff" rid="idm1841801668">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Anna</surname>
            <given-names>A. Murashkina</given-names>
          </name>
          <xref ref-type="aff" rid="idm1841702220">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tatiana</surname>
            <given-names>L. Nekhaeva</given-names>
          </name>
          <xref ref-type="aff" rid="idm1841801668">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mykhail</surname>
            <given-names>A. Maydin</given-names>
          </name>
          <xref ref-type="aff" rid="idm1841703012">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ekaterina</surname>
            <given-names>S. Artemyeva</given-names>
          </name>
          <xref ref-type="aff" rid="idm1841702220">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Anna</surname>
            <given-names>S. Artemyeva</given-names>
          </name>
          <xref ref-type="aff" rid="idm1841702220">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Irina</surname>
            <given-names>A. Baldueva</given-names>
          </name>
          <xref ref-type="aff" rid="idm1841801668">1</xref>
        </contrib>
      </contrib-group>
      <aff id="idm1841801668">
        <label>1</label>
        <addr-line>N.N. Petrov National Medicine Research Center of Oncology, Department of Oncoimmunology, 197758,                 Leningradskaya str., 68, Pesochny, Saint-Petersburg, Russian Federation </addr-line>
      </aff>
      <aff id="idm1841702220">
        <label>2</label>
        <addr-line>N.N. Petrov National Medicine Research Center of Oncology, Department of Oncoimmunology, 197758,                 Leningradskaya str., 68, Pesochny, Saint-Petersburg, Russian Federation oll N 57, Ryazan, Russia</addr-line>
      </aff>
      <aff id="idm1841703012">
        <label>3</label>
        <addr-line>N.N. Petrov National Medicine Research Center of Oncology, Department of Carcinogenesis and Aging, 197758, Leningradskaya str., 68, Pesochny, Saint-Petersburg, Russian Federation </addr-line>
      </aff>
      <aff id="idm1841703228">
        <label>*</label>
        <addr-line>Corresponding Author</addr-line>
      </aff>
      <author-notes>
        <corresp>
    
    Anna B. Danilova , <addr-line>N.N. Petrov National Medicine Research Center of Oncology, Department of             Oncoimmunology, 197758, Leningradskaya str., 68, Pesochny, Saint-Petersburg, Russian                    Federation</addr-line><email>anna_danilova@bk.ru</email></corresp>
        <fn fn-type="conflict" id="idm1842478164">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub" iso-8601-date="2022-01-19">
        <day>19</day>
        <month>01</month>
        <year>2022</year>
      </pub-date>
      <volume>4</volume>
      <issue>2</issue>
      <fpage>9</fpage>
      <lpage>29</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>01</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>01</month>
          <year>2022</year>
        </date>
        <date date-type="online">
          <day>19</day>
          <month>01</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© </copyright-statement>
        <copyright-year>2022</copyright-year>
        <copyright-holder>Anna B. Danilova, et al.</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://openaccesspub.org//jhor/article/1755">This article is available from http://openaccesspub.org//jhor/article/1755</self-uri>
      <abstract>
        <sec id="idm1841554980">
          <title>Background</title>
          <p>Human malignant cell models which               reflect the structural and physiological complexity of tumor tissue are of great importance for                   preclinical research in oncology. Spheroids/tumoroids derived from solid tumors are of great interest as cellular models mimicking the first               vascular-free growth phase of a tumor node. The fact of the identity between artificially created tumor multicellular aggregates and the real tumor tissue, however, needs to be specified, described and                   validated in order to see how closely the spheroids are biologically similar to the malignized tissues in vivo compared to the monolayer cell cultures                 traditionally used. We present here a comparison study of the characteristics of solid tumor cells of          different histogenesis (melanomas, soft tissue                   sarcomas and bone sarcomas, epithelial tumors)                 cultured in two dimensions (monolayer culture) and three dimensional space (spheroid), namely: spatial organization, multiplication, metabolic activity. </p>
        </sec>
        <sec id="idm1841552460">
          <title>Patients and Methods</title>
          <p>For the creation of 2 D and 3D cell models the cells isolated from the patient's solid tumor               fragments obtained intraoperatively were used. 15 samples of skin melanoma, 20 samples of soft tissue and osteogenic sarcomas (STBS), and 9 samples of epithelial tumors (ET). The tumor cells were all cultivated for at least 10 passages. We used phase contrast, confocal                microscopy, and immunohistochemistry to investigate spheroids and monolayer cultures. The supernatants of tumor cells grown in 2D and 3D cultures were studied using ELISA and multiplex analysis for the production of a spectrum of chemokines and cytokines supporting the immunosuppression, invasion and metastasis processes. </p>
        </sec>
        <sec id="idm1841552461">
          <title>Results</title>
          <p>Tumor specimens received were predominantly of metastatic origin (75%). In 100% of cases 2D cultures were received, in 88.6% of cases (39 out of 44) we                    succeeded in obtaining spheroids. There was no direct correlation between the efficiency of tumoroid formation and the tumor's histogenetic origin and the stage of the cancer process (primary tumor, recurrence, metastasis). The median size of spheroids by 4-5 days of cultivation with a starting concentration of 10000 cells per well was 657.14 μm for melanoma (min 400 - max 1000 μm), 571.42 μm (min 400 - max 700 μm), 507.14 μm (min              300 - max 600 μm) for soft tissue sarcomas, 650.0 μm (min 400 - max 900 μm) for osteogenic sarcomas.                    Immunochemical analysis of Ki-67, GLUT1, and Ecadherin markers was carried out for tumor tissue samples,                 single-layer tumor cultures, and tumoroids of every               patient. The distribution of the stained groups in the      spheroids was distinct from the monolayer cultures and more in accordance with the distribution of such in the tissue tumor, the number of Ki-67+ cells was increasing in the spheroids. We detected no dependence of Ki-67+ and GLUT1+ cell localization grade on spheroid size. We                identified E-cadherin in tumor tissue and tumoroids of breast carcinoma and one melanoma culture. Monolayer cultures did not express it. The increase in secretory cell activity of the solid tumor cells from 2D to 3D system was observed when CCL2, CCL3, CXCL1, CXCL16, MIF, IL10, MICA (p&lt;0.01) were investigated. </p>
        </sec>
        <sec id="idm1841552748">
          <title>Conclusion</title>
          <p>The presence of patient-specific cells of solid             tumors in a 3D environment causes activation of the             proliferative and metabolic processes as compared to monolayer cultures, which makes these models                       approximate the real world clinical picture. The                    production of chemokines that can attract to the tumor various types of immune system cells, to include their      immature versions, as well as production of cytokines and Immunosuppression factors that, when present in the             tumor microenvironment in the high concentrations,                 contribute to the formation of immune cells having                suppressive capacities occurs in the 3D cell system.                Three-dimensional model of the initial tumor nodule              formation stage thus demonstrates the forming process of tumor cells favorable for them microenvironment.                 Construction of three-dimensional models - spheroids of tumor cells of differing histogenesis demands individual approach and more thorough investigation. </p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Spheroids</kwd>
        <kwd>tumoroids</kwd>
        <kwd>solid tumors</kwd>
        <kwd>chemokines</kwd>
        <kwd>cytokines</kwd>
        <kwd>proliferation.</kwd>
      </kwd-group>
      <counts>
        <fig-count count="5"/>
        <table-count count="3"/>
        <page-count count="21"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="idm1841558292" sec-type="intro">
      <title>Introduction </title>
      <p>Solid tumors have a complex three-dimensional (3D) spatial structure, including many non-tumoral cells and the extracellular matrix, which together make up the malignant tumor microenvironment <xref ref-type="bibr" rid="ridm1841525316">1</xref>. Thereby tumor cells are usually in suboptimal growth conditions, such as hypoxia or reduced nutrient concentration, and are             affected by intercellular contacts and/or various signals from the microenvironment. In conventional                             two-dimensional (2D) single-layer cultures, most of these "environmental" signals are absent. Hence there is no              microenvironment exposure, and the biological                         characteristics of the original malignancy may be lost due to the cellular adaptation required for survival in                    vitro <xref ref-type="bibr" rid="ridm1841528700">2</xref><xref ref-type="bibr" rid="ridm1841534180">3</xref>. 2D cells cultures are exposed to a homogenous           environment: growth factors, nutrients, oxygen, and                CO2 <xref ref-type="bibr" rid="ridm1841631660">4</xref>. Conversely, cells in solid tumors are exposed to                 different gradients of biochemical molecules and                       biological signals, which can both stimulate and inhibit tumor progression <xref ref-type="bibr" rid="ridm1841388964">5</xref>. </p>
      <p>It is now well known that in 3D structures, in            addition to the possible chemical gradient's induction, three-dimensional intercellular interaction itself affects the properties of tumor cells. It includes cell structure, adhesion, mechanotransduction, and signal transduction in response to soluble factors, which in turn, regulate the general functions of cells. Altogether it is fundamentally different from traditional 2D cultivation systems <xref ref-type="bibr" rid="ridm1841385076">6</xref>. </p>
      <p>Many researchers believe that the growth kinetics of in vitro tumoroids (microsized cell spheroid                    aggregates) are similar to the growth kinetics of solid              tumors. The initial growth period of solid tumors is called the vasculinless growth phase, during which the tumor volume increases exponentially. It is followed by a               quiescent state, and a phase of new vessel formation caused by angiogenic factors <xref ref-type="bibr" rid="ridm1841381980">7</xref>. As the spheroids grow, their volume increases exponentially. When they reach a size of 200-500 µm in diameter the growth rate decreases and plateaus. Thus, spheroids' growth corresponds to the initial growth phase of the tumor node <xref ref-type="bibr" rid="ridm1841377988">8</xref>.                              Tumor spheroids are used for in vitro modeling of                malignant neoplasms to mimic their properties. Such   models are best developed for epithelial tumors: lung             cancer <xref ref-type="bibr" rid="ridm1841372228">9</xref> , cervical <xref ref-type="bibr" rid="ridm1841377988">8</xref> , pancreatic <xref ref-type="bibr" rid="ridm1841362644">10</xref>, prostate <xref ref-type="bibr" rid="ridm1841359260">11</xref>, breast <xref ref-type="bibr" rid="ridm1841364300">12</xref> , colorectal cancer <xref ref-type="bibr" rid="ridm1841341220">13</xref>. Skin melanoma       spheroids are being developed for more than 10                     years <xref ref-type="bibr" rid="ridm1841338124">14</xref> . Relatively recently, 3D cellular models for the sarcoma’s studies have begun to be developed <xref ref-type="bibr" rid="ridm1841333948">15</xref> . Thus, interest in 3D modeling to study the malignant neoplasms properties has been around for quite some time. But, the more detailed and extensive characterization and                    validation of spheroids as 3D cancer models are still             needed to understand how close they are in biological properties to malignant tissues in vivo, including                  structure, growth kinetics, gene expression, signaling pathways, and response to therapy <xref ref-type="bibr" rid="ridm1841385076">6</xref><xref ref-type="bibr" rid="ridm1841348204">16</xref>. </p>
      <p>In addition, the use of 3D models will allow                  all-important tumor characteristics to be taken into                  account to determine individual patient treatment tactics. This approach will facilitate the study of individual                  biological features of the tumors and the understanding of cancer biology in general. Here we present a comparative study of the properties of different histogenesis solid             tumors cells (melanomas, soft tissue sarcomas, and                   osteogenic sarcomas, epithelial tumors) cultured in 2D (monolayer culture) and 3D (spheroid), namely, formation features, spatial organization, proliferation, metabolic      activity, and cell motility. </p>
    </sec>
    <sec id="idm1841557860" sec-type="materials">
      <title>Materials and Methods </title>
      <p>Tumor tissue fragments surgically obtained from patients treated at N.N. Petrov National Medicine Research Center of Oncology in 2015-2020 were used as the                    material for cell cultures: 15 skin melanoma samples, 20 soft tissue and bone sarcoma (STBS) samples (7                     osteogenic sarcomas), 1 chondroblastic osteosarcoma, 4 synovial sarcomas, 3 myxofibrosarcomas, 1 pleomorphic liposarcoma, 1 embryonal rhabdomyosarcoma, 1               leiomyosarcoma, 1 alveolar sarcoma, 1 schwannoma) and 9 epithelial tumor samples (3 colorectal cancer, 2 renal cancer, 2 breast cancer, 1 non-small cell lung cancer, 1 bladder cancer). The study protocol was approved by the ethical committee of the Research Centre, all enrolled              patients or their legal representatives gave written               informed consent to obtain tumor tissue samples during surgery. Tissue samples were stored in accordance with the Declaration of Helsinki and used in accordance with the Human Tissue Act of 2004. The histological                        verification of the tumors and their localization are                presented in <xref ref-type="table" rid="idm1841968332">Table 1</xref></p>
      <table-wrap id="idm1841968332">
        <label>Table 1.</label>
        <caption>
          <title> Histological verification of patient’s tumor samples</title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <td colspan="2">tumor</td>
              <td>primary</td>
              <td>recurrence</td>
              <td colspan="2">metastatic</td>
              <td>total</td>
            </tr>
            <tr>
              <td colspan="7">melanoma</td>
            </tr>
            <tr>
              <td>melanotic</td>
              <td>spindle cell</td>
              <td>1</td>
              <td>0</td>
              <td>1</td>
              <td>soft tissue (1)</td>
              <td>2</td>
            </tr>
            <tr>
              <td/>
              <td>epithelioid cell</td>
              <td>0</td>
              <td>0</td>
              <td>3</td>
              <td>lymph nodes (3)</td>
              <td>3</td>
            </tr>
            <tr>
              <td>amelanotic</td>
              <td>spindle cell</td>
              <td>0</td>
              <td>1</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
            </tr>
            <tr>
              <td/>
              <td>epithelioid cell</td>
              <td>1</td>
              <td>1</td>
              <td>7</td>
              <td>soft tissue (3)</td>
              <td>9</td>
            </tr>
            <tr>
              <td/>
              <td/>
              <td/>
              <td/>
              <td/>
              <td>lymph nodes (2)</td>
              <td/>
            </tr>
            <tr>
              <td/>
              <td/>
              <td/>
              <td/>
              <td/>
              <td>thyroid (1) </td>
              <td/>
            </tr>
            <tr>
              <td/>
              <td/>
              <td/>
              <td/>
              <td/>
              <td>breast(1)</td>
              <td/>
            </tr>
            <tr>
              <td colspan="7">STBS subtype</td>
            </tr>
            <tr>
              <td colspan="2">osteosarcoma</td>
              <td>0</td>
              <td>0</td>
              <td>7</td>
              <td>lung (7)</td>
              <td>7</td>
            </tr>
            <tr>
              <td colspan="2">chondroblastic osteosarcoma</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
              <td>lung (1)</td>
              <td>1</td>
            </tr>
            <tr>
              <td colspan="2">pleomorphic liposarcoma</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
              <td>lung (1)</td>
              <td>1</td>
            </tr>
            <tr>
              <td colspan="2">sinovial sarcoma</td>
              <td>0</td>
              <td>2</td>
              <td>2</td>
              <td>lung (2)</td>
              <td>4</td>
            </tr>
            <tr>
              <td colspan="2">myxofibrosarcoma</td>
              <td>1</td>
              <td>1</td>
              <td>1</td>
              <td>soft tissue (1)</td>
              <td>3</td>
            </tr>
            <tr>
              <td colspan="2">leiomyosarcoma</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
              <td>lung (1)</td>
              <td>1</td>
            </tr>
            <tr>
              <td colspan="2">rabdomyosarcoma</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
              <td>lung (1)</td>
              <td>1</td>
            </tr>
            <tr>
              <td colspan="2">alveolar sarcoma</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
              <td>lung (1)</td>
              <td>1</td>
            </tr>
            <tr>
              <td colspan="2">schwannoma</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
              <td>lung (1)</td>
              <td>1</td>
            </tr>
            <tr>
              <td colspan="7">epithelial tumors</td>
            </tr>
            <tr>
              <td colspan="2">renal cancer</td>
              <td>1</td>
              <td>0</td>
              <td>1</td>
              <td>lung (1)</td>
              <td>2</td>
            </tr>
            <tr>
              <td colspan="2">colorectal cancer</td>
              <td>0</td>
              <td>0</td>
              <td>3</td>
              <td>lung (2)</td>
              <td>3</td>
            </tr>
            <tr>
              <td colspan="2"/>
              <td/>
              <td/>
              <td/>
              <td>extraperitoneal (1)</td>
              <td/>
            </tr>
            <tr>
              <td colspan="2">breast cancer</td>
              <td>1</td>
              <td>0</td>
              <td>1</td>
              <td>colon (1)</td>
              <td>2</td>
            </tr>
            <tr>
              <td colspan="2">bladder cancer</td>
              <td>0</td>
              <td>1</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
            </tr>
            <tr>
              <td colspan="2">lung cancer</td>
              <td>0</td>
              <td>0</td>
              <td>1</td>
              <td>pleural cavity (1)</td>
              <td>1</td>
            </tr>
            <tr>
              <td colspan="2">Total</td>
              <td>5</td>
              <td>6</td>
              <td>33</td>
              <td> </td>
              <td>44</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Monolayer tumor cells cultures. Freshly obtained tumor samples were mechanically disaggregated using Medimachine (Agilent Dako, USA) and passed through Filcon filter system with pore size 70 μm and 50 μm (BD Biosciences, USA). The cells were plated in DMEM/F12 media supplemented with 20% fetal bovine serum (FBS), glutamine (365 mg/l), insulin (5 μg/ml), transferrin (5 μg/ml), selenium (5 ng/ml) (Termo Fisher Scientific, CША), penicillin (100 UI/ml), streptomycin (100 μg/ml) (Sigma, CША). The tumor cells were cultured at 37 ◦C, 5% CO2, and 100% humidity in plastic flasks following the        Freshney method <xref ref-type="bibr" rid="ridm1841342948">17</xref> with our modifications <xref ref-type="bibr" rid="ridm1841311444">18</xref>.                Adherent cells were subcultured after detachment using 0.25% trypsin (Invitrogen, USA) and10 mM                              ethylenediaminetetraacetate EDTA solution (Sigma–Aldrich, USA). Tumor cell cultures were cultivated                 continuously at least for 10 passages. </p>
      <sec id="idm1841463308">
        <title>Tumor Spheroids (Tumoroids)</title>
        <p>Spheroids were obtained using a liquid overlay technique with a 96-well black plate with glass bottom Ultra-Low Attachment Surface (Corning, USA). Typically, 10,000 cells in 200 μl of complete nutrient medium were placed in the plate wells. Tumoroids were cultured in Heracel CO2 incubator (Thermo Electron LTD GmbH,              Germany) for 3 to 8 days depending on the cell line at 37ºC, in a humid atmosphere with a 5% CO2 level. During cultivation, the medium was changed on day 3. At the end of cultivation, spheroids were washed in PBS solution               (pH 7.4) for further manipulations. </p>
      </sec>
      <sec id="idm1841462804">
        <title>Structure of Spheroids</title>
        <p>Confocal microscopy techniques were used to study spheroids' structure. The washed spheroids were fixed with 10% buffered formaldehyde and stored at 4ºC for 24 h, and further stained with fluorescent dyes                 Phalloidin-Alexa488/PI at concentrations of 2 µM and 4 µM, respectively <xref ref-type="bibr" rid="ridm1841308348">19</xref>. After staining, spheroids were washed in PBS, embedded in glycerol, and imaged using a Zeiss LSM 710 confocal microscope (Zeiss, Germany), with two-channel + Z-stack viewing on an x40 objective                  (Plan-Apochromat 40x/1.4). Exposure time was 100-200 ms with filters Phalloidin-Alpha 488 - 488 nm, for PI - 546 nm. The images obtained were analyzed using ZEN              Microscope Software 2.1 on Windows7-64-bit (Zeiss,             Germany). </p>
      </sec>
      <sec id="idm1841459636">
        <title>Histological and Immunohistochemical Processing</title>
        <p>Spheroids were fixed with 10% buffered               formaldehyde at 4 °C for 24-36 h, then placed in 4% agar (Difco, USA), dehydrated with absolute isopropyl alcohol, and embedded in paraffin (Histomix, Biovitrum, RF).                      Serial paraffin sections no thicker than 4 μm using an SM2000R microtome (Leica, Germany) were made. Every tenth slice was stained with Meyer's hematoxylin and  eosin for object detection. </p>
        <p>Malignified cells grown in a monolayer on culture glasses under standard conditions were fixed in absolute acetone for 2-3 min, air-dried, placed in airtight                containers, and stored at -20°C until use. </p>
        <p>Tumor tissue samples were fixed with 10%                buffered formalin for 24 hours, dehydrated with absolute isopropyl alcohol, and embedded in paraffin (Biovitrum, Russia). Paraffin blocks of tumor tissue were treated as described above. Material from 10 patients was included in the study. </p>
        <p>Ki-67, GLUT-1, and E-cadherin antigen detection were performed in paraffin sections of tumor tissue,              monolayer tumor cultures, and tumoroids. GLUT1 Rabbit Polyclonal Antibody (Abcam, USA), Cadherin Mouse                    monoclonal antibody and Ki-67 Mouse Monoclonal                Antibody (Diagnostic BioSystems, USA) were used as             primary antibodies. EnVision FLEX HRP (Aglient Dako, Denmark) was used as a secondary antibody. The                  preparations were stained with hematoxylin (Ventana Medical Systems, Inc., Germany). </p>
        <p>Digital images were obtained using a Digital            scanning microscope Panoramic 1000 (3DHISTECH Ltd., Hungary). Lens: Carl-Zeiss Plan-Apochromat 40×Corr / NA 0.95. Camera: Adimec QUARTZ Q-12A180 with resolution 69 Mp/mm2, using CaseViewer 2.2.1 software (3DHISTECH Ltd., Hungary). </p>
      </sec>
      <sec id="idm1841460428">
        <title>Elisa</title>
        <p>Supernatants of monolayer cell cultures (2D) and spheroids (3D) were tested. Conditioned medium was   collected 7 days after the beginning of cultivation. Tumor cell culture supernatants were stored at -20°C and thawed at 4°C immediately before determining the concentration of the test substances. Sandwich-type enzyme-linked            immunosorbent assay Duoset ELISA Kit (R&amp;D Systems, USA) was used to detect NKG2D receptor-ligand of             cytotoxic Tlymphocytes and natural killer MICA. The             optical density in each well was measured at 450 nm using a Thermo Scientific Multiscan EX microplate reader (Thermo LabSystems Inc., USA). Transformation Growth factor β1 (TGF β1) was detected with Bender MedSystems GmbH, Austria. </p>
      </sec>
      <sec id="idm1841458916">
        <title>Multiplex Analysis</title>
        <p>A Bio-Plex® 200 multiplex analyzer (Bio-Rad, USA) and a Bio-Plex Pro™ Human Chemokine Panel,                 40-Plex (Bio-Rad, USA) were used to detect major                    cytokines and chemokines in supernatants of 2D and 3D tumor cell cultures. The concentrations of the following analytes were analyzed: 6Ckine/CCL21, BCA1/CXCL13, CTACK/CCL27, ENA-78/CXCL5, Eotaxin/CCL11, Eotaxin-2/CCL24, Eotaxin3/CCL26, Fractalkine/CX3CL1, GCP-2/CXCL6, GM-CSF, Gro-α/CXCL1, Gro-β CXCL2, I309/CCL1, IFN-ϒ, IL-1β, IL-2, IL-4, IL-6, IL-8/CXCL8, IL-10, IL-16,           IP-10/CXCL10, ITAC/CXCL11, MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13, MDC/CCL22, MIF, MIG/CXCL9, MIP-1α/CCL3, MIP-1δ/CCL15, MIP-3α/CCL20, MIP-3β/CCL19, MPIF1/CCL23, SCYB16/CXCL16, SDF-1α+β/CXCL12, TARC/CCL17, TECK/CCL25, TNF-α. </p>
      </sec>
      <sec id="idm1841460212">
        <title>Statistical Analysis</title>
        <p>Data were statistically analyzed using Wilcoxon W-test for connected samples. Differences were considered statistically significant at p&lt;0.05 For data storage,            processing, statistical analysis, and visualization Microsoft Excel 2019 (Microsoft Corporation, USA) was used.              Systematization, statistical analysis, and data visualization were performed using R v. 4.0.1. <xref ref-type="bibr" rid="ridm1841304460">20</xref></p>
      </sec>
    </sec>
    <sec id="idm1841459348" sec-type="results">
      <title>Results </title>
      <p>Tumor cell cultures. As a result of tumor                      fragments disaggregation, 15 cultures of skin melanoma, 20 STBS cultures, 8 cultures of epithelial tumors cells were obtained, as described in the "Materials and Methods"   section. Seventy-five percent of the samples were of             metastatic origin (33 of 44), 11.4% were obtained from the primary tumor (5 of 44) and 13.6% were from                recurrent disease (6 of 44). Morphologically, all the              obtained tumor cultures were highly heterogeneous              within the same histological type (<xref ref-type="fig" rid="idm1841759052">Figure 1</xref>, I). </p>
      <fig id="idm1841759052">
        <label>Figure 1.</label>
        <caption>
          <title> Мorphology of the established solid tumor cell cultures and spheroids I-monolayer tumor cell cultures, II-spheroids composed of tumor cells (monospheroids). 1, 2 – alveolar sarcoma #927, 10 passage; 3, 4 – melanoma #860, 35 passage; 5, 6 – leiomyosarcoma #699, 16 passage; 7, 8 – melanoma #912, 25 passage; 9, 10 – rhabdomyosarcoma #862, 20 passage; 11, 12 – melanoma #929, 51 passage; 13, 14 – synovial sarcoma #716, 25 passage; 15, 16 – renal cancer #584, 40 passage; 17,  18 – myxofibrosarcoma #728, 19 passage; 19, 20 – colon cancer #485, 12 passage; 21, 22 – osteosarcoma #921, 12 passage; 23, 24 – bladder cancer #875, 15 passage.                Inverted microscope, phase contrast, 100 µm scale value. </title>
        </caption>
        <graphic xlink:href="images/image1.jpg" mime-subtype="jpg"/>
      </fig>
      <p>Adhesion growth was typical for all tumor                  cultures except breast cancer culture # 973, with a               semi-suspension growth type that tended to                           spontaneously form rounded cell aggregates resembling spheroids. </p>
      <p>Spheroid formation. During the Liquid overlay technique cultivation, three stages of spheroid formation were observed. For 1-2 days the tumor cells formed              disc-like structures at the bottom of the well. On days 2-3, they united into unstable cell aggregates with uneven     edges, which could be destroyed by any physical impact. On days 3-5, the aggregates gained cell mass and, as a rule, formed a dense rounded spheroid with smooth edges      (<xref ref-type="fig" rid="idm1841756100">Figure 2</xref>). In 88.6% of cases (39 out of 44), spheroids                suitable for further manipulations were obtained. </p>
      <fig id="idm1841756100">
        <label>Figure 2.</label>
        <caption>
          <title> Stages of spheroid formation  1 - formation of tumor cells disc on the bottom of the well;                          2 - aggregation of tumor cells; 3 - compaction and growth of tumor cells. melanoma cell culture #912, 33 passage. Zeiss Primo Vert phase contrast microscope (10x 0.25 Ph1). The scale bar is 100 µm. </title>
        </caption>
        <graphic xlink:href="images/image2.jpg" mime-subtype="jpg"/>
      </fig>
      <p>Direct dependence of tumoroid formation efficacy on the histogenesis of tumor cells and the stage of the carcinogenesis the material was taken (primary tumor, relapse, metastasis) was not revealed. The process had an individual character and depended on the internal        properties of particular cell culture. Among the cultured melanoma cells (MC), only in one (6.7%) aggregation was not observed; 5 cultures demonstrated the formation of loose, weakly stable spheroids (33.3%); in some cases, the cell aggregate retained rather a disk-like rather than a spherical shape. The rest of MC samples (60%) formed dense stable spheroids, often with a well-defined marginal zone (<xref ref-type="fig" rid="idm1841759052">Figure 1</xref>-4, 1-8, 1-12). Generally, STBS cells showed response to induced aggregation and quickly formed dense stable spheroids (95%) (<xref ref-type="fig" rid="idm1841759052">Figure 1</xref>-2, 1-6, 1-10, 1-14,           1-18, 1-22), except for pleomorphic liposarcoma # 702, which grew on a low-adhesive surface in separate               aggregates up to 30 microns in diameter and disintegrated due to medium change or spheroid transferring. Among epithelial tumor cells, a third of the cultures did not form tumoroids, including 1 kidney cancer culture #291 and 2 colorectal cancer cultures. Kidney cancer culture # 291 formed loose unstable spheroids (<xref ref-type="fig" rid="idm1841759052">Figure 1</xref>-16). Breast cancer cells # 973 had a semi-suspension growth pattern and were prone to spontaneous aggregation, that is, they      existed in culture as conglomerates of 50-400 cells. To obtain tumoroids from this culture, native spheroids were disintegrated at a given starting inoculum concentration, then cell suspension was placed in a drop or added to a culture plate. However, the newly formed small                        aggregates disintegrated within 1–2 days. Combining             several native spheroids in one drop or plate well resulted in the formation of one large spheroid. At the same time, another breast cancer culture # 512 showed a pronounced adhesive growth in a monolayer and formed a dense      spheroid with smooth edges. </p>
      <p>The average size of spheroids by 4-5 days of cultivation with a starting concentration of 10,000 cells per well was 657.14 μm for melanoma (min 400 - max 1000 μm), 571.42 μm for soft tissue sarcomas (min 400 - max 700 μm), 507.14 microns for osteogenic sarcomas (min 300 - max 600 microns), and 650.0 microns for epithelial tumors (min 400 - max 900 microns).</p>
      <p> Spheroidal organization. According to confocal microscopy, the structural organization of spheroids from different histogenesis tumor cells had similar features (<xref ref-type="fig" rid="idm1841752428">Figure 3</xref>). </p>
      <fig id="idm1841752428">
        <label>Figure 3.</label>
        <caption>
          <title> Confocal microscopy analysis of tumoroids’ structure    A – melanoma cell culture #912, B – myxofibrosarcoma cell culture #728, C –leiomyosarcoma cell culture #699, D – melanoma cell culture #226, E – breast cancer cell culture #973. PI - Propidium iodide (red, nuclei), Phalloidin-Alexa-488 (green, F-actin). Legend: arrow 1 indicates inner spheroid layer and F-actin outgrowths, arrow 2 indicates proliferating rounded cells at the spheroid periphery, arrow 3 indicates stained nuclei. Scale bar is 50 µm for cell cultures #699, #728, #226, 100 µm for cell              culture #912, #973. </title>
        </caption>
        <graphic xlink:href="images/image3.jpg" mime-subtype="jpg"/>
      </fig>
      <p>In the central zone of tumoroids, cells showed a typical mesenchymal morphology, characterized by an elongated form and rich F-actin outgrowths, traced throughout the tumoroid. On the periphery, there were predominantly rounded proliferating cells without              outgrowths, but with increased F-actin expression, which may indicate a high potential for invasion. Different             intensity of F-actin expression was found in tumoroids of various origins, and it was least expressed in STBS                spheroids (<xref ref-type="fig" rid="idm1841752428">Figure 3</xref>). </p>
      <p>Proliferative and metabolic features of tumor cells in 2D and 3D experimental systems. </p>
      <p>Immunochemical analysis of Ki-67 (cell                       proliferation marker), GLUT1 (unidirectional glucose transporter), and E-cadherin, (intercellular contacts) was carried out in tumor tissue samples, monolayer cultures, and tumoroids of each patient. </p>
      <p>Analysis of monolayer tumor cultures                       preparations stained with Mayer's hemalaun and eosin showed that the cultured tumor cells were well spread and occupied a significant area (<xref ref-type="fig" rid="idm1841750988">Figure 4</xref>). Tumoroids                 structure largely reproduced the structure of tumor tissue in vessels free areas. Peripheral spheroid cells were round in shape, and closer to the center cells were more                 compact, since the space was limited by neighboring cells and the extracellular matrix. </p>
      <fig id="idm1841750988">
        <label>Figure 4.</label>
        <caption>
          <title> Identification of Ki-67, GLUT1, E-cadherin in solid tumor cells from different experimental systems. A - #921 osteosarcoma, 10             passage, spheroid ⊘ 752.7 μm; B - #912 melanoma, 19 passage, ⊘ 683 μm; C - #982 myxofibrosarcoma, 33 passage, ⊘ 611.8 μm; D - #973 breast cancer, 27 passage, ⊘ 690 μm. Monolayer culture - 20 μm scale bar; spheroid - 100 μm scale bar; tumor tissue - 20 μm scale bar. From left to right: hematoxylin-eosin staining; proliferative activity marker Ki-67; GLUT1 - glucose transporter protein; cell adhesion protein                  E-cadherin.  different experimental systems. </title>
        </caption>
        <graphic xlink:href="images/image4.jpg" mime-subtype="jpg"/>
      </fig>
      <p>The distribution of Ki-67+ and GLUT1+ cells in the spheroid structure was individual even within tumors of similar histogenesis, in particular, in the spheroids of myxofibrosarcoma, osteosarcoma, and melanoma (<xref ref-type="table" rid="idm1841749260">Table 2</xref>, <xref ref-type="fig" rid="idm1841750988">Figure 4</xref>). At the same time, the distribution of stained cells in the spheroids differed from the monolayer culture and was more consistent with the distribution of those in the tumor tissue. No dependence in Ki-67+ and GLUT1+ cells localization on the spheroid size was found (<xref ref-type="table" rid="idm1841749260">Table 2</xref>). </p>
      <table-wrap id="idm1841749260">
        <label>Table 2.</label>
        <caption>
          <title> Comparative analysis of the detection of markers of proliferation, metabolic activity and intercellular contacts in different cell systems in vitro and in vivo</title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <td> Culture</td>
              <td>Spheroid                                                                                               diameter, μm</td>
              <td colspan="9">ANTIGENS</td>
            </tr>
            <tr>
              <td/>
              <td/>
              <td colspan="3">KI-67 (% stain cells)</td>
              <td colspan="3">GLUT1 (+present/-absent)</td>
              <td colspan="3">E-cadherin (+present/-absent)</td>
            </tr>
            <tr>
              <td/>
              <td/>
              <td>tumor</td>
              <td>2D</td>
              <td>3D/localisation</td>
              <td>tumor</td>
              <td>2D</td>
              <td>3D/localisation</td>
              <td>tumor</td>
              <td>2D</td>
              <td>3D</td>
            </tr>
            <tr>
              <td>#699leiomyosarcoma</td>
              <td>310,8</td>
              <td>22</td>
              <td>10</td>
              <td>15diffuse</td>
              <td>+</td>
              <td>-</td>
              <td>+diffuse</td>
              <td>-</td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td>#862
rabdomyosarcoma</td>
              <td>612</td>
              <td>12</td>
              <td>5</td>
              <td>14diffuse</td>
              <td>±</td>
              <td>-</td>
              <td>++spheroid centre</td>
              <td>-</td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td>#716 synovialsarcoma</td>
              <td>620,7</td>
              <td>65</td>
              <td>70</td>
              <td>78spheroid centre</td>
              <td>+</td>
              <td>-</td>
              <td>+spheroid centre</td>
              <td>-</td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td>#728myxofibrosarcoma</td>
              <td>550,6</td>
              <td>25</td>
              <td>12</td>
              <td>35diffuse</td>
              <td>+</td>
              <td>-</td>
              <td>+spheroid centre</td>
              <td>-</td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td>#982myxofibrosarcoma</td>
              <td>611,8</td>
              <td>45</td>
              <td>18</td>
              <td>78diffuse</td>
              <td>++</td>
              <td>±</td>
              <td>++diffuse</td>
              <td>-</td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td>#793osteosarcoma</td>
              <td>417,2</td>
              <td>52</td>
              <td>10</td>
              <td>12diffuse</td>
              <td>±</td>
              <td>-</td>
              <td>±diffuse</td>
              <td>-</td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td>ОС #921osteosarcoma</td>
              <td>752,7</td>
              <td>48</td>
              <td>5</td>
              <td>45spheroid periphery</td>
              <td>+</td>
              <td>-</td>
              <td>++spheroid centre</td>
              <td>-</td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td>#912 melanoma</td>
              <td>683</td>
              <td>67</td>
              <td>80</td>
              <td>85 - spheroid periphery</td>
              <td>++</td>
              <td>-</td>
              <td>++spheroid centre</td>
              <td>-</td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td/>
              <td/>
              <td/>
              <td/>
              <td>10 – spheroid centre</td>
              <td/>
              <td/>
              <td/>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td>#929 melanoma</td>
              <td>680,8</td>
              <td>45</td>
              <td>25</td>
              <td>55diffuse</td>
              <td>++</td>
              <td>±</td>
              <td>±diffuse</td>
              <td>+</td>
              <td>-</td>
              <td>±</td>
            </tr>
            <tr>
              <td>#973 breast cancer</td>
              <td>690</td>
              <td>88</td>
              <td>no data</td>
              <td>93diffuse</td>
              <td>+++</td>
              <td>no data</td>
              <td>+++diffuse</td>
              <td>++</td>
              <td>no data</td>
              <td>++</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The number of Ki-67+ cells in monolayer cultures was lower than in spheroids and/or in tumor tissue. In most cases, an increase in the number of Ki-67+ cells              correlated with an increase in the tumoroid size. It can be assumed that the presence of spheroid architecture, more complex in comparison with monolayer cultures, as well as the presence of a nutrient gradient, and necrotic               nucleus inside, increases the expression of this factor. In spheroids, peripheral localization of Ki67+ cells (<xref ref-type="table" rid="idm1841749260">Table 2</xref>) was observed in 2 cases out of 10 (melanoma #912 and osteosarcoma #921); central localization - in 1 case out of 10 (synovial sarcoma culture #716) and diffuse - in 7             cases out of 10. </p>
      <p>It is assumed that tumoroids can represent a model of a hypoxic niche of tumor cells in vitro. Increased hypoxia in tumors induces GLUT-1 protein expression, carrying out unidirectional glucose transport across the plasma membrane. GLUT-1 expression in tumor spheroids and tumor tissue was found. No GLUT-1 expression in all monolayer samples was revealed, except in melanoma #929, where weak cytoplasm staining in 7% of cells was observed. </p>
      <p>In several cases, GLUT-1 gradient distribution in spheroids was revealed (<xref ref-type="table" rid="idm1841749260">Table 2</xref>, <xref ref-type="fig" rid="idm1841750988">Figure 4</xref> A, B). At the same time, GLUT-1 + mycofibrosarcoma and breast cancer cells had a diffuse distribution inward tumoroid, despite its significant size (&gt; 600 µm in diameter) (<xref ref-type="fig" rid="idm1841750988">Figure 4</xref> C, D). The intensity of GLUT-1 expression, assessed by the intensity of the immunocytochemical reaction, depended on the spheroid size: the larger the size, the more pronounced the staining was. In particular, in melanoma #912              spheroid, a decrease in staining intensity from the center to the periphery was observed (Fig. 4B). Such a                 distribution of GLUT-1 may indicate a decrease in glucose concentration from the periphery to the center of the             tumoroid. The increased GLUT-1 expression in tumor spheroids demonstrates the change in glucose metabolism in 3D cultured tumor cells as compared to 2D, which brings the considered 3D cell models closer to tumor            tissue. </p>
      <p>E-cadherin in breast cancer #973 tumor tissue and tumoroids was revealed (<xref ref-type="table" rid="idm1841749260">Table 2</xref>, <xref ref-type="fig" rid="idm1841750988">Figure 4</xref>D). E-cadherin was also detected in MC #929 tumor tissue; very weak staining was observed in the tumoroid, while the                   monolayer culture did not express it. In other cases,                    E-cadherin was not detected. </p>
      <p>Secretory functions in spheroids cells. Statistically significant differences in the secretory activity in 2D and 3D cultures of solid tumor cells in CCL2 study were                observed (a powerful factor of monocyte chemotaxis in mammals). CCL2 mean concentration in the conditioned medium of spheroids was 1707.16 pg/ml (min 150.74 - max 6316.8), while in the supernatant of monolayer              cultures - 848.79 pg/ml (min 4.91 - max 1973.08);              p = 0.04126 (<xref ref-type="fig" rid="idm1841596836">Figure 5</xref>-1). There were also statistically              significant differences in CCL3 production (macrophage inflammatory protein 1- alpha, involved in acute                  inflammation, in the recruitment and activation of                   polymorphonuclear leukocytes by binding to CCR1, CCR4, and CCR5 receptors): 1.82 pg/ml (min 0, 11 - max 20.24) compared to 3.88 pg/ml (min 1.10 - max 1230.28) in the monolayer and tumoroids, respectively (p = 0.00427)   (<xref ref-type="fig" rid="idm1841596836">Figure 5</xref>-2).</p>
      <fig id="idm1841596836">
        <label>Figure 5.</label>
        <caption>
          <title> Graphical representation of individual differences in chemokine and cytokine production of 2D and 3D tumor cells cultures. Abscissa: cultivation conditions (2D and 3D), ordinate: concentration of test                substance in tumor cell culture supernatants, pg/ml. 1 - MCP-1 / CCL2, p=0.04126; 2 - MIP-1α / CCL3, p=0.00427; 3 - SCYB16 / CXCL16, p=0.00427; 4 - Gro-α / CXCL1, p=0.0105; 5 - MIF, p=0.00854; 6 - IL-10, p=0.00006; 7 - MICA, p=0.00001. </title>
        </caption>
        <graphic xlink:href="images/image5.jpg" mime-subtype="jpg"/>
      </fig>
      <p>MIF secretion (a factor inhibiting macrophages migration, an evolutionarily ancient cytokine that                     regulates many processes in the body, i.e., inflammation) also changed depending on the cultivation conditions: 33.55 ng/ml (min 30.84 - max 82.66) in 2D cultures up to 62.05 ng/ml (min 37.69 - max 175.31) in spheroids                       (p = 0.00854) (<xref ref-type="fig" rid="idm1841596836">Figure 5</xref>-5) </p>
      <p>A statistically significant increase in Interleukin 10 (IL10) expression (plays a role in tumor-induced                immunosuppression) was observed in 3D culture                    compared to the monolayer: the median was 116.71 pg/ml (min 7.70 - max 649.19) and 17.32 pg/ml                              (min 1.42 - max 107.39), p = 0.00006, respectively (<xref ref-type="fig" rid="idm1841596836">Figure 5</xref>-6). Statistically significant increase in MICA production in 3D cultures: 363.55 pg/ml (min 57.68 - max 3537.5) compared to the monolayer: 90.2 pg/ml (min 15.63 - max 1818.5) was found, p = 0.00001(<xref ref-type="fig" rid="idm1841596836">Figure 5</xref>-7). </p>
      <p>Studying the remaining analytes, no statistically significant differences were found in general, but                     individual analysis showed interesting features for tumor cells in individual patients. An almost 4-fold increase in chemokine CCL21 level, which under normal conditions is a chemoattractant for naive T-lymphocytes possessing CCR7 receptor, was found in spheroid supernatants of myxofibrosarcoma #728 (2D / 3D - 246.61 / 891.25 pg/ml). An increase in CCL21 concentration in kidney cancer # 291 tumoroids was observed (2D / 3D - 357.76 / 428.64 pg/ml). Chemoattractant for B-lymphocytes CXCL13 was detected in high concentrations in the supernatants of myxofibrosarcoma #728 and lung cancer #1014 cultures (<xref ref-type="table" rid="idm1841594172">Table 3</xref>). Interestingly, among all studied cultures,                 spheroids #728 demonstrated an increase in the                  production of almost all homeostatic and inflammatory chemokines (<xref ref-type="table" rid="idm1841594172">Table 3</xref>). Also, according to the intensity of the increase in the specific synthetic functions under             consideration during the transition from monolayer              culture to tumoroids, lung cancer cell cultures #1014, rhabdomyosarcoma #862, and melanoma #916 were              noted. All these malignant cells cultures were obtained from metastatic formations, the tumor process was         aggressive, tumors were resistant to standard therapies, which led to the rapid death of the patients. </p>
      <table-wrap id="idm1841594172">
        <label>Table 3.</label>
        <caption>
          <title> Homeostatic and inflammatory chemokines/cytokines content in supernatants of individual 2D and 3D human solid tumour cell models</title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <td>Analytes, pg/ml</td>
              <td colspan="8">Cultures</td>
            </tr>
            <tr>
              <td/>
              <td colspan="2">#728</td>
              <td colspan="2">#1014</td>
              <td colspan="2">#862</td>
              <td colspan="2">#916</td>
            </tr>
            <tr>
              <td/>
              <td>2D</td>
              <td>3D</td>
              <td>2D</td>
              <td>3D</td>
              <td>2D</td>
              <td>3D</td>
              <td>2D</td>
              <td>3D</td>
            </tr>
            <tr>
              <td>CCL1</td>
              <td>28,7</td>
              <td>86,6↑</td>
              <td>288,6</td>
              <td>51,5</td>
              <td>38,3</td>
              <td>38,6↑</td>
              <td>71,7</td>
              <td>74,9↑</td>
            </tr>
            <tr>
              <td>CCL2</td>
              <td>37,9</td>
              <td>6316,8↑</td>
              <td>3032,5</td>
              <td>1006,9</td>
              <td>7338,5</td>
              <td>2522,1</td>
              <td>2618,1</td>
              <td>2582,9</td>
            </tr>
            <tr>
              <td>CCL3</td>
              <td>9,1</td>
              <td>1230,3↑</td>
              <td>16,3</td>
              <td>42,9↑</td>
              <td>1,3</td>
              <td>1,9↑</td>
              <td>3,1</td>
              <td>11,7↑</td>
            </tr>
            <tr>
              <td>CCL7</td>
              <td>33,3</td>
              <td>358,1↑</td>
              <td>542,2</td>
              <td>4323,8↑</td>
              <td>702,2</td>
              <td>4458,9↑</td>
              <td>194,7</td>
              <td>210,7↑</td>
            </tr>
            <tr>
              <td>CCL8</td>
              <td>0,58</td>
              <td>3620,3↑</td>
              <td>697,4</td>
              <td>632,5</td>
              <td>6302,6</td>
              <td>158,6</td>
              <td>2,5</td>
              <td>2,7↑</td>
            </tr>
            <tr>
              <td>CCL11</td>
              <td>10,8</td>
              <td>33,6↑</td>
              <td>37,6</td>
              <td>24,6</td>
              <td>224,6</td>
              <td>45,5</td>
              <td>25,7</td>
              <td>24,9</td>
            </tr>
            <tr>
              <td>CCL13</td>
              <td>67,4</td>
              <td>117,7↑</td>
              <td>376,9</td>
              <td>223,7</td>
              <td>379,1</td>
              <td>273,6</td>
              <td>106,6</td>
              <td>71,9</td>
            </tr>
            <tr>
              <td>CCL15</td>
              <td>11,6</td>
              <td>580,7↑</td>
              <td>357,4</td>
              <td>58,9</td>
              <td>14,6</td>
              <td>15,6↑</td>
              <td>127,1</td>
              <td>154,7↑</td>
            </tr>
            <tr>
              <td>CCL17</td>
              <td>7,1</td>
              <td>57,3↑</td>
              <td>64,9</td>
              <td>20,8</td>
              <td>15,03</td>
              <td>16,1</td>
              <td>26,1</td>
              <td>27,8↑</td>
            </tr>
            <tr>
              <td>CCL19</td>
              <td>46,9</td>
              <td>190,2↑</td>
              <td>199,8</td>
              <td>155,8</td>
              <td>235,8</td>
              <td>99,5</td>
              <td>141,4</td>
              <td>131,5</td>
            </tr>
            <tr>
              <td>CCL20</td>
              <td>11,8</td>
              <td>6300,3↑</td>
              <td>28,9</td>
              <td>443,1↑</td>
              <td>4,7</td>
              <td>106,2↑</td>
              <td>2177,8</td>
              <td>3730,8↑</td>
            </tr>
            <tr>
              <td>CCL21</td>
              <td>246,6</td>
              <td>891,3↑</td>
              <td>620,7</td>
              <td>535,2</td>
              <td>446,5</td>
              <td>468,4↑</td>
              <td>743,9</td>
              <td>767,9↑</td>
            </tr>
            <tr>
              <td>CCL22</td>
              <td>15,3</td>
              <td>251,2↑</td>
              <td>4954,3</td>
              <td>194,1</td>
              <td>148,6</td>
              <td>32,9</td>
              <td>30,7</td>
              <td>28,4</td>
            </tr>
            <tr>
              <td>CCL23</td>
              <td>4,3</td>
              <td>24,5↑</td>
              <td>490,1</td>
              <td>25,4</td>
              <td>8,6</td>
              <td>9,3↑</td>
              <td>19,3</td>
              <td>19,3</td>
            </tr>
            <tr>
              <td>CCL24</td>
              <td>45,8</td>
              <td>77,5↑</td>
              <td>617,6</td>
              <td>73,4</td>
              <td>48,8</td>
              <td>56,2↑</td>
              <td>69,4</td>
              <td>65,1</td>
            </tr>
            <tr>
              <td>CCL25</td>
              <td>103,7</td>
              <td>906,4↑</td>
              <td>524,1</td>
              <td>529,2↑</td>
              <td>222,4</td>
              <td>328,7↑</td>
              <td>639,6</td>
              <td>705,3↑</td>
            </tr>
            <tr>
              <td>CCL26</td>
              <td>1040,8</td>
              <td>28524↑</td>
              <td>215,9</td>
              <td>577,6↑</td>
              <td>46,7</td>
              <td>782,2↑</td>
              <td>90,3</td>
              <td>107,2↑</td>
            </tr>
            <tr>
              <td>CCL27</td>
              <td>8,5</td>
              <td>47,3↑</td>
              <td>28,5</td>
              <td>25,9</td>
              <td>18,36</td>
              <td>15,3</td>
              <td>24,1</td>
              <td>22,3</td>
            </tr>
            <tr>
              <td>CXCL1*</td>
              <td>7,3</td>
              <td>15,7↑</td>
              <td>26,4</td>
              <td>45,7↑</td>
              <td>4,8</td>
              <td>15,1↑</td>
              <td>10,6</td>
              <td>53,4↑</td>
            </tr>
            <tr>
              <td>CXCL2</td>
              <td>386,6</td>
              <td>10328↑</td>
              <td>1162,7</td>
              <td>4033,5↑</td>
              <td>86,4</td>
              <td>1040,9↑</td>
              <td>578,1</td>
              <td>236,2</td>
            </tr>
            <tr>
              <td>CXCL5</td>
              <td>1394,3</td>
              <td>15382↑</td>
              <td>11782</td>
              <td>9469,7</td>
              <td>2026,6</td>
              <td>2160,1↑</td>
              <td>2702,7</td>
              <td>2107,6</td>
            </tr>
            <tr>
              <td>CXCL6</td>
              <td>16,3</td>
              <td>502,9↑</td>
              <td>5678,5</td>
              <td>12311,8↑</td>
              <td>1038,8</td>
              <td>6279,6↑</td>
              <td>42,5</td>
              <td>46,8↑</td>
            </tr>
            <tr>
              <td>CXCL9</td>
              <td>14,7</td>
              <td>4773,6↑</td>
              <td>12378</td>
              <td>904,4</td>
              <td>37,9</td>
              <td>41,7↑</td>
              <td>72,03</td>
              <td>69,05</td>
            </tr>
            <tr>
              <td>CXCL10</td>
              <td>22,2</td>
              <td>16798↑</td>
              <td>644,1</td>
              <td>16164↑</td>
              <td>28,2</td>
              <td>27,9</td>
              <td>3099,3</td>
              <td>4888,4↑</td>
            </tr>
            <tr>
              <td>CXCL11</td>
              <td>8,8</td>
              <td>3320,2↑</td>
              <td>403,3</td>
              <td>65,1</td>
              <td>3,07</td>
              <td>4,09↑</td>
              <td>141,8</td>
              <td>235,8↑</td>
            </tr>
            <tr>
              <td>CXCL12</td>
              <td>316,4</td>
              <td>6454,8↑</td>
              <td>517,1</td>
              <td>4796,9↑</td>
              <td>170,9</td>
              <td>264,3↑</td>
              <td>215,2</td>
              <td>216,3↑</td>
            </tr>
            <tr>
              <td>CXCL13</td>
              <td>0,48</td>
              <td>5,65↑</td>
              <td>40,6</td>
              <td>2,38</td>
              <td>1,21</td>
              <td>1,13</td>
              <td>3,36</td>
              <td>3,79↑</td>
            </tr>
            <tr>
              <td>CXCL16</td>
              <td>5,4</td>
              <td>177,51↑</td>
              <td>575,1</td>
              <td>408,6</td>
              <td>151,5</td>
              <td>43,9</td>
              <td>11,5</td>
              <td>11,0</td>
            </tr>
            <tr>
              <td>CX3CL1</td>
              <td>71,4</td>
              <td>3002,4↑</td>
              <td>126,6</td>
              <td>361,9↑</td>
              <td>40,6</td>
              <td>184,8↑</td>
              <td>3611,6</td>
              <td>4952,4↑</td>
            </tr>
            <tr>
              <td>GM-CSF</td>
              <td>624,7</td>
              <td>15277↑</td>
              <td>30,1</td>
              <td>37,1↑</td>
              <td>37,9</td>
              <td>24,5</td>
              <td>68,4</td>
              <td>68,8↑</td>
            </tr>
            <tr>
              <td>IFN-ϒ</td>
              <td>13,8</td>
              <td>117,5↑</td>
              <td>45,9</td>
              <td>36,8</td>
              <td>24,08</td>
              <td>26,1↑</td>
              <td>77,5</td>
              <td>85,3↑</td>
            </tr>
            <tr>
              <td>IL-1β</td>
              <td>11,9</td>
              <td>35,1↑</td>
              <td>17,5</td>
              <td>19,3↑</td>
              <td>21,03</td>
              <td>20,7</td>
              <td>27,7</td>
              <td>23,9</td>
            </tr>
            <tr>
              <td>IL-2</td>
              <td>3,5</td>
              <td>29,02↑</td>
              <td>17,3</td>
              <td>9,65</td>
              <td>6,4</td>
              <td>7,2↑</td>
              <td>19,9</td>
              <td>23,8↑</td>
            </tr>
            <tr>
              <td>IL-4</td>
              <td>10,6</td>
              <td>41,8↑</td>
              <td>13,01</td>
              <td>10,05</td>
              <td>7,5</td>
              <td>9,6↑</td>
              <td>12,7</td>
              <td>12,07</td>
            </tr>
            <tr>
              <td>IL-6*</td>
              <td>0,2</td>
              <td>34,08↑</td>
              <td>25,3</td>
              <td>36,1↑</td>
              <td>36,5</td>
              <td>25,1</td>
              <td>5,09</td>
              <td>1,7</td>
            </tr>
            <tr>
              <td>IL-8</td>
              <td>2668,2</td>
              <td>10128↑</td>
              <td>8787,7</td>
              <td>9231,4↑</td>
              <td>8886,9</td>
              <td>9589,8↑</td>
              <td>9699,5</td>
              <td>7426,1</td>
            </tr>
            <tr>
              <td>IL-10</td>
              <td>26,3</td>
              <td>61,3↑</td>
              <td>75,3</td>
              <td>51,4</td>
              <td>34,2</td>
              <td>41,1↑</td>
              <td>59,03</td>
              <td>502,8↑</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Tumor necrosis factor (TNF-α) expression in    melanomas' tumoroids was increased in comparison with other groups of tumors. In particular, in culture #860 cells the production of this factor was increased from 4.88 pg/ml (monolayer) to 8.43 pg/ml (tumoroids); in culture #929 - from 4.51 pg/ml to 15.17 pg/ml; in culture                        #916 - from 15.82 pg/ml to 54.26 pg/ml; in culture #912 - from 5.46 pg/ml to 21.48 pg/ml; and culture #519 - from 0.51 pg/ml ml to 5.77 pg/ml. </p>
      <p>No statistically significant increase in TGFβ1 in 3D culture compared to 2D was observed for all types of              tumors: 2.123 (0.948–4.174) ng/ml in spheroids versus 2.478 (0.594–5.57) ng/ml in the monolayer, p = 0.46829. However, when analyzed individually, TGF-β1 production was doubled in 3D culture of LMS # 699 cells compared to 2D culture (1.53 ng/ml and 0.69 ng/ml, respectively). A similar trend was found in melanoma #912 cells - 3D / 2D 3.82 ng/ml and 2.47 ng/ml, respectively; in                              myxofibrosarcoma #728 cells - 3D / 2D 2.91 ng/ml and 3.73 ng/ml, respectively; in lung cancer #1014 cells - 3D / 2D 1.92 ng/ml and 2.37 ng/ml, respectively. </p>
    </sec>
    <sec id="idm1841132164" sec-type="discussion">
      <title>Discussion </title>
      <p>Nowadays in preclinical trials, 3D in vitro models are becoming more in demand for the development of new drugs and therapeutic approaches in malignancy                   treatment <xref ref-type="bibr" rid="ridm1841348204">16</xref><xref ref-type="bibr" rid="ridm1841316484">21</xref><xref ref-type="bibr" rid="ridm1841315980">22</xref>. </p>
      <p>One of the directions is the study of malignant neoplasms cells isolated from patients in                                   three-dimensional biological systems in order to recreate the molecular complexity of carcinogenic mechanisms and search for ways to increase sensitivity to pharmacological treatment <xref ref-type="bibr" rid="ridm1841293732">23</xref>. According to some researchers, the                       generation of spheroids is especially important for the study of sarcomas, since the growth rate, cell morphology, and intercellular interactions in spheroids mimic primary tumors quite well <xref ref-type="bibr" rid="ridm1841333948">15</xref>. </p>
      <p>In the current study, we performed a comparative analysis of the efficiency of spheroids formation from various histogenesis solid tumor cells, isolated from the             patients, and changes in the properties of cultured                 malignant cells, depending on the spatial organization of the cell model in vitro. We studied the ability to form spheroids in 15 skin melanoma cultures, 20 STBS, 9              epithelial origin tumor cultures. </p>
      <p>We obtained malignant cells cultures of various histogenesis with stable proliferative characteristics and passed at least 10 passages. All the obtained cultures were used to create spheroids; however, in a number of cases, stable spheroids were not formed. The overall efficiency of spheroid formation was 88.6% (39 out of 44), and did not depend on the histogenesis, but was probably associated with the stage of oncogenesis. Interestingly, the first works on the study of solid tumor spheroid formation have already indicated the genetic determination of               malignant cells in the process of tumor progression. Thus, in J.M. Yuhas et al. (1978) study of breast cancer cell lines, spheroids formation was shown for cells isolated from primary and metastatic solid foci, in contrast to cells from pleural effusion and ascitic fluid <xref ref-type="bibr" rid="ridm1841290996">24</xref>. In our study, tumor cell cultures that did not form spheroids were of                         metastatic origin: 1 sample of skin melanoma, 2 -                      colorectal cancer, and 1 - pleomorphic liposarcoma                (lung metastasis). One kidney cancer culture was derived from a primary tumor that had clinically extremely                 aggressive potential. Cultures that were characterized by the formation of loose unstable spheroids (5 skin                     melanoma, 1 kidney cancer, 1 lung cancer, 1 breast                  cancer) were also isolated from solid metastases, pleural fluid, and recurrence. </p>
      <p>The spheroid formation process consists of at least three phases: initial aggregation of isolated cells, compaction of the spheroid, and its growth. Our                     observations coincide with other researchers'                       opinions <sup>25–27</sup>. It was found that cells in spheroids, as in tumors, deposit extracellular matrix components:             collagen IV, laminin, fibronectin, proteoglycans, tenascin, etc. <xref ref-type="bibr" rid="ridm1841281204">28</xref>. The close physical interaction between tumor cells and the extracellular matrix due to α5- and                          β1-integrins <xref ref-type="bibr" rid="ridm1841267724">29</xref> and contacts between tumor cells due to E-cadherins <xref ref-type="bibr" rid="ridm1841262180">30</xref> increase spheroid density, and create a certain barrier for the penetration and distribution of    substances coming from outside <xref ref-type="bibr" rid="ridm1841259948">31</xref><xref ref-type="bibr" rid="ridm1841258652">32</xref>. In addition,                 intracellular components such as actin and microtubules also contribute to the formation of 3D structures <xref ref-type="bibr" rid="ridm1841270964">33</xref><xref ref-type="bibr" rid="ridm1841244364">34</xref>. We examined the obtained spheroids of breast cancer, STBS, and skin melanoma using confocal microscopy and found that their structural organization had similar               features in different cell cultures. The central zone cells had a large number of outgrowths and protrusions                   containing F-actin, the peripheral zone cells were                    predominantly rounded and showed increased expression of F-actin, which may indicate a high potential for invasion</p>
      <p>We did not detect E-cadherin expression in STBS and melanomas tumoroids. Normally, E-cadherin is                  expressed on the surface of epithelial cells, promoting the formation of the tight junction between cells <xref ref-type="bibr" rid="ridm1841241772">35</xref>. The                presence of E-cadherin is also a characteristic of                       non-epithelial origin tumors. It is believed that malignant cells that have lost this protein exhibit the potential for invasion and metastasis. We observed explicit E-cadherin expression only in tumoroids formed from breast cancer cells. The distribution of E-cadherin molecules was                   uniform in tumoroids and in the tumor tissue itself. A study by A. Amann et al. (2014) of E-cadherin expression in lung cancer cell line A549 spheroids demonstrated that the loss of these cell adhesion receptors leads to a                     predominance of the mesenchymal phenotype and                 invasive activity of tumor cells <xref ref-type="bibr" rid="ridm1841372228">9</xref> . </p>
      <p>Many researchers believe that the kinetics of             tumoroid growth in vitro is similar to the kinetics of solid tumors growth in vivo. The initial period of solid tumor growth is called the phase of avascular growth. During this period the tumor volume increases exponentially, then plateaus, followed by a phase of new vessels formation caused by angiogenic factors <xref ref-type="bibr" rid="ridm1841237236">36</xref><xref ref-type="bibr" rid="ridm1841234716">37</xref>. Under the action of matrix metalloproteinases (MMP-2, MMP-9), the                 extracellular matrix is remodeled, and tumor cells acquire the ability to invade and metastasize <xref ref-type="bibr" rid="ridm1841234428">38</xref>. In the process of tumoroids growth, their volume increases                              exponentially. Then, upon reaching a size of 200-500 μm in diameter, the growth rate decreases and reaches a              plateau. Thus, spheroid's growth corresponds to the initial phase of tumor node growth <xref ref-type="bibr" rid="ridm1841377988">8</xref>. In our study, the largest stable spheroids (700-1000 μm in diameter) were                   obtained from skin melanoma cells, the smallest diameter (up to 400 μm) was possessed by spheroids from muscle tumor cells (rhabdo and leiomyosarcoma), other types of cells formed tumoroids with a diameter of 500-700 μm. </p>
      <p>In the literature, one can find the opinion that, as solid tumors, spheroids are characterized by certain               cellular zoning, the presence of which becomes more                pronounced with an increase in the spheroid size. The outer layer is described with rapidly proliferating cells, the middle layer with senescent or dormant cells, and the inner layer containing necrotic cells <xref ref-type="bibr" rid="ridm1841230036">39</xref>. The size of                  spheroids can be from 100 to 1000 μm, and spheroids with a radius of 200 micrometers and more will have             proliferating and resting zones, while spheroids much larger in radius may also contain a necrotic zone due to lack of nutrients and restriction of oxygen transport <xref ref-type="bibr" rid="ridm1841224132">40</xref>. In creating cell models, it seems important to characterize the proliferative properties of tumor cell cultures isolated from the patient's body. One of the most significant              markers of proliferation is Ki67, presented in mitotically active cells throughout the entire mitotic cycle and absent in resting and differentiated cells <xref ref-type="bibr" rid="ridm1841221756">41</xref> . In the literature, one can find the opinion that, as solid tumors, spheroids are characterized by certain cellular zoning, the presence of which becomes more pronounced with an increase in the spheroid size. The outer layer is described with               rapidly proliferating cells, the middle layer with senescent or dormant cells, and the inner layer containing necrotic cells <xref ref-type="bibr" rid="ridm1841230036">39</xref>. The size of spheroids can be from 100 to 1000 μm, and spheroids with a radius of 200 micrometers and more will have proliferating and resting zones, while spheroids much larger in radius may also contain a              necrotic zone due to lack of nutrients and restriction of oxygen transport <xref ref-type="bibr" rid="ridm1841224132">40</xref>. In creating cell models, it seems important to characterize the proliferative properties of tumor cell cultures isolated from the patient's body. One of the most significant markers of proliferation is Ki67,       presented in mitotically active cells throughout the entire mitotic cycle and absent in resting and differentiated               cells <xref ref-type="bibr" rid="ridm1841221756">41</xref> . </p>
      <p>The microenvironment in the inner part of the spheroid is acidified (pH range 6.5-7.2) due to the active pyruvate to lactate convert by tumor cells in hypoxia <xref ref-type="bibr" rid="ridm1841248684">42</xref>. This phenomenon is similar to the Warburg effect                associated with lactate accumulation in solid                       tumors <xref ref-type="bibr" rid="ridm1841258652">32</xref><xref ref-type="bibr" rid="ridm1841184700">43</xref>. In response to the low pH, malignant cells in senescent and necrotic zones begin to actively produce factors for proliferation and survival <xref ref-type="bibr" rid="ridm1841182972">44</xref><xref ref-type="bibr" rid="ridm1841178436">45</xref> . </p>
      <p>We carried out a comparative study of the                 structure of spheroids consisting of different histotype origin malignant cells. We used proliferation marker Ki67 and the metabolic marker - glucose transporter protein GLUT1, which carries out unidirectional glucose transfer through the membrane under hypoxic conditions. In our 3D models, Ki-67 distribution was of two varieties:              peripheral in the case when proliferating cells were              concentrated in the marginal zone of the spheroid, and diffuse throughout the thickness of the tumoroid. In the study of human chondrosarcoma multicellular spheroids A. Voissiere et al. (2017) noted that on the 7th day of              cultivation, Ki-67 distribution in the spheroids was                uniform, while with the growth of the spheroid (14th and 20th days of cultivation) Ki-67 was mainly localized in the periphery <xref ref-type="bibr" rid="ridm1841175412">46</xref>. We did not find a clear dependence of             Ki-67+ cells localization on the size and type of the               spheroid. </p>
      <p>M. Vinci et al. have demonstrated GLUT-1 uniform distribution in spheroids <xref ref-type="bibr" rid="ridm1841173468">47</xref>. In our study, we noted two types of GLUT-1 distribution in spheroids: uniform and gradient from the center to the periphery. At the same time, no clear dependence of GLUT-1 + cells localization on the size and type of spheroid was observed. In                    particular, the leiomyosarcoma spheroid had a diameter of 310.8 μm and diffuse distribution of Ki-67+ and GLUT-1 + populations; osteosarcoma spheroid was 752.7 μm in            diameter with the marginal location of Ki-67+ and central location of GLUT-1 + . However, the rest of the spheroids were 550 - 690 μm in diameter and showed a different distribution of the studied markers, including a uniform one. We believe that this phenomenon needs more            detailed study. Interestingly, Commander R. et al. (2020) demonstrated that during 3D spreading, cells that are                  heterogeneous in metabolic activity can be identified as "leader" cells if predominantly use mitochondrial                  respiration, and "subsequent" cells if rely on increased glucose uptake and, accordingly, actively produce GLUT1 maintaining an increased level of glucose uptake to              maintain proliferation <xref ref-type="bibr" rid="ridm1841171884">48</xref></p>
      <p>Tumor cells are in constant interaction with the surrounding microenvironment, and in a sense, a tumor can be considered as a kind of multicomponent “ecosystem” where malignant cells optimize                         microenvironmental resources to create the best                 conditions for their proliferation <xref ref-type="bibr" rid="ridm1841165476">49</xref><xref ref-type="bibr" rid="ridm1841164468">50</xref>. Many soluble    factors produced by tumor cells promote the emergence of complex local and regional immunosuppressive networks. Those favor tumor growth, invasion, and metastasis by inhibiting the activity of immune system cells directly    involved in the recognition and elimination of malignant cells, reprogramming of myeloid cells such as neutrophils, monocytes, macrophages, forming a favorable and                 protective niche for a metastatic growth <xref ref-type="bibr" rid="ridm1841160724">51</xref>. In 2D and 3D tumor systems, we compared the production of several chemokines and cytokines that provide immunosuppression, invasion, and metastasis. We established that tumor cells in the 3D system presented more pronounced                 secretory activity about immunosuppressive factors and factors that ensure their mobility. </p>
      <p>In 3D systems, CCR2 and CCR3 chemokines            production was increased. As is known, CCL2–CCR2                signaling pathway is associated with the recruitment of macrophages and regulatory T-lymphocytes into the          tumor <xref ref-type="bibr" rid="ridm1841190100">52</xref>, which may contribute to tumor progression. In addition, CCL2 shows protumorigenic action, which promotes cancer and metastasis development <xref ref-type="bibr" rid="ridm1841188300">53</xref>.            Certain cultures of tumor cells in spheroids produced            increased amounts of CXCL16 and CXCL12. The                     chemokine CXCL16 affects the migration of NKT and            immature lymphoid cells <xref ref-type="bibr" rid="ridm1841132092">54</xref>. CXCL12 – CXCR4 signaling pathway is involved in the survival, proliferation,              metastasis, and drug resistance of tumor cells <xref ref-type="bibr" rid="ridm1841128492">55</xref> . </p>
      <p>The interaction of MICA ligand on tumor cells with NKG2D activation receptor on NK cells and cytotoxic T-lymphocytes leads to their activation with subsequent elimination of tumor cells. However, in most tumors MICA ligand is overproduced causing the “sloughing off” of stress-induced MICA molecules from the surface of              malignant cells. Thenafter the interaction of immune cells with such a soluble form of the molecule, leads to the loss of their effector functions <xref ref-type="bibr" rid="ridm1841127268">56</xref>. We have observed the              activation of this mechanism in tumoroids. </p>
      <p>We have observed an increase in Interleukin-10 production. It promotes the recruitment and activation of regulatory T-lymphocytes (Treg), the acquisition of a tolerogenic phenotype by dendritic cells, and suppression of the activity of CD8+ T-lymphocytes and NK cells <xref ref-type="bibr" rid="ridm1841124532">57</xref>. Being in 3D space, tumor cells enhanced the production of a macrophage migration inhibition factor (MIF), which is known as a tumor cell- and stromal cell-derived mediator of stromal cell recruitment, polarization, and                     differentiation <xref ref-type="bibr" rid="ridm1841119636">58</xref> . TGF-β is a multipotent growth factor that affects differentiation, proliferation, apoptosis, and matrix production in normal and tumor cells. TGF-β acts as a tumor suppressor and promotor, triggering many processes that regulate tumor growth. As a tumor                 promotor, it induces tumor cells migration and stimulates the epithelial-mesenchymal transition <xref ref-type="bibr" rid="ridm1841116252">59</xref>. In a number of spheroids, an increase in TGF-β secretion was                            observed. The change in the secretory profile of malignant cells depending on the cultivation conditions                         demonstrates that to simulate the real spectrum of factors presented in the tumor microenvironment, it is necessary to reproduce the habitat of malignant cells, bringing it as close as possible to the natural one. </p>
    </sec>
    <sec id="idm1841128348" sec-type="conclusions">
      <title>Conclusion </title>
      <p>Cell models of human malignant neoplasms               reflecting the structural and physiological complexity of tumor tissue are very important for preclinical studies in oncology. Our studies have demonstrated that in                         contradiction to monolayer cultures, the existence of a 3D environment of solid tumor cells of the patients leads to the activation of proliferative and metabolic processes, bringing these models closer to a real clinical situation. In a 3D cellular system, the synthetic activity of tumor cells is enhanced. On the one hand, that leads to the increased production of various chemokines capable of attracting various types of immune cells, including their immature forms. On the other hand, cytokines and                                    immunosuppression factors begin to produce more active and being present in the tumor microenvironment in high concentrations, contribute to the formation of cells of the immune system with suppressive potential. Tumoroid cells show signs of increased proliferative activity,                 mobility, invasion potential, and epithelial-mesenchymal transition. Thus, it becomes clear that 3D spheroids                  creation from tumor cells of various histogenesis requires an individual approach and more in-depth study. </p>
    </sec>
    <sec id="idm1841129716">
      <title>Authors’ Contributions </title>
      <p>All authors participated in the design and writing of the manuscript. </p>
    </sec>
    <sec id="idm1841129212">
      <title>Funding </title>
      <p>This work was financially supported by the               Russian Foundation for Basic Research (Project #18- 29-09014) to the Irina Baldueva </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ridm1841525316">
        <label>1.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Ishiguro</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications</article-title>
          <date>
            <year>2017</year>
          </date>
          <source>Cancer Science</source>
          <volume>108</volume>
          <fpage>283</fpage>
          <lpage>289</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841528700">
        <label>2.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Park</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Development of organoid-based drug metabolism model</article-title>
          <date>
            <year>2019</year>
          </date>
          <source>Toxicol. Appl. Pharmacol</source>
          <volume>385</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841534180">
        <label>3.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Nazari</surname>
            <given-names>S S</given-names>
          </name>
          <article-title>Generation of 3D Tumor Spheroids with Encapsulating Basement Membranes for Invasion Studies</article-title>
          <date>
            <year>2020</year>
          </date>
          <source>Curr. Protoc. Cell Biol</source>
          <volume>87</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841631660">
        <label>4.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>E</surname>
            <given-names>A Taha</given-names>
          </name>
          <article-title>Knockout of MMP3 weakens solid tumor organoids and cancer extracellular vesicles. Cancers (Basel)</article-title>
          <date>
            <year>2020</year>
          </date>
          <volume>12</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841388964">
        <label>5.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Jensen</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Teng</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Is It Time to Start Transitioning From 2D to 3D Cell Culture? Frontiers in</article-title>
          <date>
            <year>2020</year>
          </date>
          <source>Molecular Biosciences</source>
          <volume>7</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841385076">
        <label>6.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Baker</surname>
            <given-names>B M</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C S</given-names>
          </name>
          <article-title>Deconstructing the third dimension-how 3D culture microenvironments alter cellular cues</article-title>
          <date>
            <year>2012</year>
          </date>
          <source>Journal of Cell Science</source>
          <volume>125</volume>
          <fpage>3015</fpage>
          <lpage>3024</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841381980">
        <label>7.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Tatullo</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Organoids in Translational Oncology</article-title>
          <date>
            <year>2020</year>
          </date>
          <source>J. Clin. Med</source>
          <volume>9</volume>
          <fpage>2774</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841377988">
        <label>8.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>E</surname>
            <given-names>C Costa</given-names>
          </name>
          <name>
            <surname>V</surname>
            <given-names>M Gaspar</given-names>
          </name>
          <name>
            <surname>Coutinho</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>I</surname>
            <given-names>J Correia</given-names>
          </name>
          <article-title>Optimization of liquid overlay technique to formulate heterogenic 3D co-cultures models</article-title>
          <date>
            <year>2014</year>
          </date>
          <source>Biotechnol. Bioeng</source>
          <volume>111</volume>
          <fpage>1672</fpage>
          <lpage>1685</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841372228">
        <label>9.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Amann</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Development of an innovative 3D cell culture system to study tumour - Stroma interactions in non-small cell lung cancer cells. PLoS One 9</article-title>
          <date>
            <year>2014</year>
          </date>
        </mixed-citation>
      </ref>
      <ref id="ridm1841362644">
        <label>10.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Lazzari</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Multicellular spheroid based on a triple co-culture: A novel 3D model to mimic pancreatic tumor complexity</article-title>
          <date>
            <year>2018</year>
          </date>
          <source>Acta Biomater</source>
          <volume>78</volume>
          <fpage>296</fpage>
          <lpage>307</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841359260">
        <label>11.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Linxweiler</surname>
            <given-names>J</given-names>
          </name>
          <article-title>three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer</article-title>
          <date>
            <year>2019</year>
          </date>
          <source>J. Cancer Res. Clin. Oncol</source>
          <volume>145</volume>
          <fpage>551</fpage>
          <lpage>559</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841364300">
        <label>12.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Froehlich</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Generation of Multicellular Breast Cancer Tumor Spheroids: Comparison of Different Protocols</article-title>
          <date>
            <year>2016</year>
          </date>
          <source>Journal of Mammary Gland Biology and Neoplasia</source>
          <volume>21</volume>
          <fpage>89</fpage>
          <lpage>98</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841341220">
        <label>13.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Jeppesen</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine</article-title>
          <date>
            <year>2017</year>
          </date>
          <source>PLoS One</source>
          <volume>12</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841338124">
        <label>14.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Marconi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Quadri</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Saltari</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pincelli</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Progress in melanoma modelling in vitro</article-title>
          <date>
            <year>2018</year>
          </date>
          <source>Experimental Dermatology</source>
          <volume>27</volume>
          <fpage>578</fpage>
          <lpage>586</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841333948">
        <label>15.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Colella</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Sarcoma spheroids and organoids-Promising tools in the era of personalized medicine</article-title>
          <date>
            <year>2018</year>
          </date>
          <source>International Journal of Molecular Sciences</source>
          <volume>19</volume>
          <fpage>615</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841348204">
        <label>16.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Gilazieva</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Ponomarev</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rutland</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rizvanov</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Solovyeva</surname>
            <given-names>V</given-names>
          </name>
          <article-title>Promising applications of tumor spheroids and organoids for personalized medicine</article-title>
          <date>
            <year>2020</year>
          </date>
          <source>Cancers</source>
          <volume>12</volume>
          <fpage>1</fpage>
          <lpage>19</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841342948">
        <label>17.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Capes-Davis</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>R</surname>
            <given-names>I Freshney</given-names>
          </name>
          <article-title>Freshney’s Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications</article-title>
          <date>
            <year>2021</year>
          </date>
        </mixed-citation>
      </ref>
      <ref id="ridm1841311444">
        <label>18.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>A</surname>
            <given-names>O Danilov</given-names>
          </name>
          <article-title>An improved procedure for autologous gene-modified vaccine preparation for active specific immunotherapy of disseminated solid tumors. Вопросы онкологии 50</article-title>
          <date>
            <year>2004</year>
          </date>
          <fpage>219</fpage>
          <lpage>227</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841308348">
        <label>19.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Geraldo</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Simon</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>D</surname>
            <given-names>M Vignjevic</given-names>
          </name>
          <article-title>Revealing the cytoskeletal organization of invasive cancer cells in 3D</article-title>
          <date>
            <year>2013</year>
          </date>
          <source>J. Vis. Exp</source>
        </mixed-citation>
      </ref>
      <ref id="ridm1841304460">
        <label>20.</label>
        <mixed-citation xlink:type="simple" publication-type="book">
          <name>
            <surname>B</surname>
            <given-names>S Everitt</given-names>
          </name>
          <name>
            <surname>Pickles</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Statistical Aspects of the Design and Analysis of Clinical Trials</article-title>
          <date>
            <year>2004</year>
          </date>
          <chapter-title>Statistical Aspects of the Design and Analysis of Clinical Trials (PUBLISHED BY IMPERIAL COLLEGE PRESS AND DISTRIBUTED BY WORLD SCIENTIFIC PUBLISHING CO</chapter-title>
        </mixed-citation>
      </ref>
      <ref id="ridm1841316484">
        <label>21.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Feder-Mengus</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Ghosh</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Reschner</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>G</surname>
            <given-names>C Spagnoli</given-names>
          </name>
          <article-title>New dimensions in tumor immunology: what does 3D culture reveal? Trends Mol</article-title>
          <date>
            <year>2008</year>
          </date>
          <source>Med</source>
          <volume>14</volume>
          <fpage>333</fpage>
          <lpage>340</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841315980">
        <label>22.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>C</surname>
            <given-names>J Lovitt</given-names>
          </name>
          <name>
            <surname>T</surname>
            <given-names>B Shelper</given-names>
          </name>
          <name>
            <surname>V</surname>
            <given-names>M Avery</given-names>
          </name>
          <article-title>Advanced cell culture techniques for cancer drug discovery</article-title>
          <date>
            <year>2014</year>
          </date>
          <source>Biology</source>
          <volume>3</volume>
          <fpage>345</fpage>
          <lpage>367</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841293732">
        <label>23.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Heredia-Soto</surname>
            <given-names>V</given-names>
          </name>
          <article-title>3D Culture Modelling: An Emerging Approach for Translational Cancer Research in Sarcomas</article-title>
          <date>
            <year>2019</year>
          </date>
          <source>Curr. Med. Chem</source>
          <volume>27</volume>
          <fpage>4778</fpage>
          <lpage>4788</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841290996">
        <label>24.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>J</surname>
            <given-names>M Yuhas</given-names>
          </name>
          <name>
            <surname>A</surname>
            <given-names>E Tarleton</given-names>
          </name>
          <name>
            <surname>K</surname>
            <given-names>B Molzen</given-names>
          </name>
          <article-title>Multicellular Tumor Spheroid Formation by Breast Cancer Cells Isolated from Different Sites. Cancer Res</article-title>
          <date>
            <year>1978</year>
          </date>
          <volume>38</volume>
          <fpage>2486</fpage>
          <lpage>2491</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841286676">
        <label>25.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>R</surname>
            <given-names>M Enmon</given-names>
          </name>
          <name>
            <surname>K</surname>
            <given-names>C O’Connor</given-names>
          </name>
          <name>
            <surname>D</surname>
            <given-names>J Lacks</given-names>
          </name>
          <name>
            <surname>D</surname>
            <given-names>K Schwartz</given-names>
          </name>
          <name>
            <surname>R</surname>
            <given-names>S Dotson</given-names>
          </name>
          <article-title>Dynamics of spheroid self-assembly in liquid-overlay culture of DU 145 human prostate cancer cells</article-title>
          <date>
            <year>2001</year>
          </date>
          <source>Biotechnol. Bioeng</source>
          <volume>72</volume>
          <fpage>579</fpage>
          <lpage>591</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841283580">
        <label>26.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>R</surname>
            <given-names>Z Lin</given-names>
          </name>
          <name>
            <surname>L</surname>
            <given-names>F Chou</given-names>
          </name>
          <name>
            <surname>Chien</surname>
            <given-names>C C M</given-names>
          </name>
          <name>
            <surname>H</surname>
            <given-names>Y Chang</given-names>
          </name>
          <article-title>Dynamic analysis of hepatoma spheroid formation: Roles of E-cadherin and β1-integrin. Cell Tissue Res</article-title>
          <date>
            <year>2006</year>
          </date>
          <volume>324</volume>
          <fpage>411</fpage>
          <lpage>422</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841283508">
        <label>27.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>L</surname>
            <given-names>B Weiswald</given-names>
          </name>
          <name>
            <surname>Bellet</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Dangles-Marie</surname>
            <given-names>V</given-names>
          </name>
          <article-title>Spherical Cancer Models in Tumor Biology</article-title>
          <date>
            <year>2015</year>
          </date>
          <source>Neoplasia (United States)</source>
          <volume>17</volume>
          <fpage>1</fpage>
          <lpage>15</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841281204">
        <label>28.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>H</surname>
            <given-names>F Chan</given-names>
          </name>
          <article-title>Rapid formation of multicellular spheroids in double-emulsion droplets with controllable microenvironment</article-title>
          <date>
            <year>2013</year>
          </date>
          <source>Sci. Rep</source>
          <volume>3</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841267724">
        <label>29.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>C</surname>
            <given-names>K Miranti</given-names>
          </name>
          <name>
            <surname>J</surname>
            <given-names>S Brugge</given-names>
          </name>
          <article-title>Sensing the environment: A historical perspective on integrin signal transduction</article-title>
          <date>
            <year>2002</year>
          </date>
          <source>Nat. Cell Biol</source>
          <volume>4</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841262180">
        <label>30.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Smyrek</surname>
            <given-names>I</given-names>
          </name>
          <article-title>E-cadherin, actin, microtubules and FAK dominate different spheroid formation phases and important elements of tissue integrity</article-title>
          <date>
            <year>2019</year>
          </date>
          <source>Biol. Open</source>
          <volume>8</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841259948">
        <label>31.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>I</surname>
            <given-names>F Tannock</given-names>
          </name>
          <name>
            <surname>C</surname>
            <given-names>M Lee</given-names>
          </name>
          <name>
            <surname>J</surname>
            <given-names>K Tunggal</given-names>
          </name>
          <name>
            <surname>Cowan</surname>
            <given-names>D S M</given-names>
          </name>
          <name>
            <surname>M</surname>
            <given-names>J Egorin</given-names>
          </name>
          <article-title>Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy</article-title>
          <date>
            <year>2002</year>
          </date>
          <source>Clin. Cancer Res</source>
          <volume>8</volume>
          <fpage>878</fpage>
          <lpage>884</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841258652">
        <label>32.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Trédan</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>C</surname>
            <given-names>M Galmarini</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>I</surname>
            <given-names>F Tannock</given-names>
          </name>
          <article-title>Drug resistance and the solid tumor microenvironment</article-title>
          <date>
            <year>2007</year>
          </date>
          <source>Journal of the National Cancer Institute</source>
          <volume>99</volume>
          <fpage>1441</fpage>
          <lpage>1454</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841270964">
        <label>33.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>E</surname>
            <given-names>S Tzanakakis</given-names>
          </name>
          <name>
            <surname>L</surname>
            <given-names>K Hansen</given-names>
          </name>
          <name>
            <surname>W</surname>
            <given-names>S Hu</given-names>
          </name>
          <article-title>The role of actin filaments and microtubules in hepatocyte spheroid self-assembly</article-title>
          <date>
            <year>2001</year>
          </date>
          <source>Cell Motil. Cytoskeleton</source>
          <volume>48</volume>
          <fpage>175</fpage>
          <lpage>189</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841244364">
        <label>34.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Yoshii</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation</article-title>
          <date>
            <year>2011</year>
          </date>
          <source>Biomaterials</source>
          <volume>32</volume>
          <fpage>6052</fpage>
          <lpage>6058</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841241772">
        <label>35.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Wong</surname>
            <given-names>SHM</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>C M</given-names>
          </name>
          <name>
            <surname>Chuah</surname>
            <given-names>L H</given-names>
          </name>
          <name>
            <surname>Leong</surname>
            <given-names>C O</given-names>
          </name>
          <name>
            <surname>Ngai</surname>
            <given-names>S C</given-names>
          </name>
          <article-title>E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Critical Reviews in Oncology/Hematology</article-title>
          <date>
            <year>2018</year>
          </date>
          <volume>121</volume>
          <fpage>11</fpage>
          <lpage>22</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841237236">
        <label>36.</label>
        <mixed-citation xlink:type="simple" publication-type="book">
          <name>
            <surname>Ward</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>King</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Mathematical modelling of avascular-tumour growth -</article-title>
          <date>
            <year>1997</year>
          </date>
          <chapter-title>PubMed. Mathematical Medicine and Biology</chapter-title>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>39</fpage>
          <lpage>69</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841234716">
        <label>37.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Raica</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>A</surname>
            <given-names>M Cimpean</given-names>
          </name>
          <name>
            <surname>Ribatti</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Angiogenesis in pre-malignant conditions</article-title>
          <date>
            <year>2009</year>
          </date>
          <source>European Journal of Cancer</source>
          <volume>45</volume>
          <fpage>1924</fpage>
          <lpage>1934</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841234428">
        <label>38.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>M</surname>
            <given-names>Van Dijk</given-names>
          </name>
          <name>
            <surname>S</surname>
            <given-names>A Göransson</given-names>
          </name>
          <name>
            <surname>Strömblad</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Cell to extracellular matrix interactions and their reciprocal nature in cancer</article-title>
          <date>
            <year>2013</year>
          </date>
          <source>Experimental Cell Research</source>
          <volume>319</volume>
          <fpage>1663</fpage>
          <lpage>1670</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841230036">
        <label>39.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Mehta</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>A</surname>
            <given-names>Y Hsiao</given-names>
          </name>
          <name>
            <surname>Ingram</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>G</surname>
            <given-names>D Luker</given-names>
          </name>
          <name>
            <surname>Takayama</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy</article-title>
          <date>
            <year>2012</year>
          </date>
          <source>J. Control. Release</source>
          <volume>164</volume>
          <fpage>192</fpage>
          <lpage>204</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841224132">
        <label>40.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>D</surname>
            <given-names>P Ivanov</given-names>
          </name>
          <article-title>Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres. PLoS One 9</article-title>
          <date>
            <year>2014</year>
          </date>
        </mixed-citation>
      </ref>
      <ref id="ridm1841221756">
        <label>41.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Juríková</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Danihel</surname>
            <given-names>Ľ</given-names>
          </name>
          <name>
            <surname>Polák</surname>
            <given-names>Š</given-names>
          </name>
          <name>
            <surname>Varga</surname>
            <given-names>I</given-names>
          </name>
          <article-title>Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer</article-title>
          <date>
            <year>2016</year>
          </date>
          <source>Acta Histochemica</source>
          <volume>118</volume>
          <fpage>544</fpage>
          <lpage>552</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841248684">
        <label>42.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>K</surname>
            <given-names>O Alfarouk</given-names>
          </name>
          <article-title>Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question</article-title>
          <date>
            <year>2014</year>
          </date>
          <source>Oncoscience</source>
          <volume>1</volume>
          <fpage>777</fpage>
          <lpage>802</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841184700">
        <label>43.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>J</surname>
            <given-names>W Kim</given-names>
          </name>
          <name>
            <surname>C</surname>
            <given-names>V Dang</given-names>
          </name>
          <article-title>Cancer’s molecular sweet tooth and the warburg effect</article-title>
          <date>
            <year>2006</year>
          </date>
          <source>Cancer Research</source>
          <volume>66</volume>
          <fpage>8927</fpage>
          <lpage>8930</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841182972">
        <label>44.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>A</surname>
            <given-names>L Harris</given-names>
          </name>
          <article-title>Hypoxia - A key regulatory factor in tumour growth</article-title>
          <date>
            <year>2002</year>
          </date>
          <source>Nature Reviews Cancer</source>
          <volume>2</volume>
          <fpage>38</fpage>
          <lpage>47</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841178436">
        <label>45.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>S</surname>
            <given-names>K Parks</given-names>
          </name>
          <name>
            <surname>Cormerais</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Pouysségur</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Hypoxia and cellular metabolism in tumour pathophysiology</article-title>
          <date>
            <year>2017</year>
          </date>
          <source>Journal of Physiology</source>
          <volume>595</volume>
          <fpage>2439</fpage>
          <lpage>2450</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841175412">
        <label>46.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Voissiere</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing</article-title>
          <date>
            <year>2017</year>
          </date>
          <source>PLoS One</source>
          <volume>12</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841173468">
        <label>47.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Vinci</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation</article-title>
          <date>
            <year>2012</year>
          </date>
          <source>BMC Biol</source>
          <volume>10</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841171884">
        <label>48.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Commander</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Subpopulation targeting of pyruvate dehydrogenase and GLUT1 decouples metabolic heterogeneity during collective cancer cell invasion</article-title>
          <date>
            <year>2020</year>
          </date>
          <source>Nat. Commun</source>
          <volume>11</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841165476">
        <label>49.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Hui</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Tumor microenvironment: Sanctuary of the devil</article-title>
          <date>
            <year>2015</year>
          </date>
          <source>Cancer Lett</source>
          <volume>368</volume>
          <fpage>7</fpage>
          <lpage>13</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841164468">
        <label>50.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Sleeboom</surname>
            <given-names>J J F</given-names>
          </name>
          <name>
            <surname>H</surname>
            <given-names>E Amirabadi</given-names>
          </name>
          <name>
            <surname>Nair</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>C</surname>
            <given-names>M Sahlgren</given-names>
          </name>
          <name>
            <surname>Toonder</surname>
            <given-names>J M J Den</given-names>
          </name>
          <article-title>Metastasis in context: Modeling the tumor microenvironment with cancer-on-a-chip approaches</article-title>
          <date>
            <year>2018</year>
          </date>
          <source>DMM Dis. Model. Mech</source>
          <volume>11</volume>
        </mixed-citation>
      </ref>
      <ref id="ridm1841160724">
        <label>51.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Russo</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>M</surname>
            <given-names>P Protti</given-names>
          </name>
          <article-title>Tumor-derived factors affecting immune cells</article-title>
          <date>
            <year>2017</year>
          </date>
          <source>Cytokine Growth Factor Rev</source>
          <volume>36</volume>
          <fpage>79</fpage>
          <lpage>87</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841190100">
        <label>52.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>D</surname>
            <given-names>F Quail</given-names>
          </name>
          <name>
            <surname>J</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Microenvironmental regulation of tumor progression and metastasis</article-title>
          <date>
            <year>2013</year>
          </date>
          <source>Nature Medicine</source>
          <volume>19</volume>
          <fpage>1423</fpage>
          <lpage>1437</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841188300">
        <label>53.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>S</surname>
            <given-names>Y Lim</given-names>
          </name>
          <name>
            <surname>A</surname>
            <given-names>E Yuzhalin</given-names>
          </name>
          <name>
            <surname>A</surname>
            <given-names>N Gordon-Weeks</given-names>
          </name>
          <name>
            <surname>R</surname>
            <given-names>J Muschel</given-names>
          </name>
          <article-title>Targeting the CCL2- CCR2 signaling axis in cancer metastasis</article-title>
          <date>
            <year>2016</year>
          </date>
          <source>Oncotarget</source>
          <volume>7</volume>
          <fpage>28697</fpage>
          <lpage>28710</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841132092">
        <label>54.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Bachelerie</surname>
            <given-names>F</given-names>
          </name>
          <article-title>International union of pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacological Reviews</article-title>
          <date>
            <year>2014</year>
          </date>
          <volume>66</volume>
          <fpage>1</fpage>
          <lpage>79</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841128492">
        <label>55.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>S</surname>
            <given-names>L Ham</given-names>
          </name>
          <article-title>Three-dimensional tumor model mimics stromal - breast cancer cells signaling. Oncotarget 9</article-title>
          <date>
            <year>2018</year>
          </date>
          <fpage>249</fpage>
          <lpage>267</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841127268">
        <label>56.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Andrade</surname>
            <given-names>L F De</given-names>
          </name>
          <article-title>Inhibition of MICA and MICB shedding elicits NK-cell-mediated immunity against tumors resistant to cytotoxic T cells</article-title>
          <date>
            <year>2020</year>
          </date>
          <source>Cancer Immunol. Res</source>
          <volume>8</volume>
          <fpage>769</fpage>
          <lpage>780</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841124532">
        <label>57.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Belli</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Targeting the microenvironment in solid tumors</article-title>
          <date>
            <year>2018</year>
          </date>
          <source>Cancer Treat. Rev</source>
          <volume>65</volume>
          <fpage>22</fpage>
          <lpage>32</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841119636">
        <label>58.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>R</surname>
            <given-names>A Mitchell</given-names>
          </name>
          <name>
            <surname>Yaddanapudi</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Stromal-dependent tumor promotion by MIF family members</article-title>
          <date>
            <year>2014</year>
          </date>
          <source>Cellular Signalling</source>
          <volume>26</volume>
          <fpage>2969</fpage>
          <lpage>2978</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841116252">
        <label>59.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Plou</surname>
            <given-names>J</given-names>
          </name>
          <article-title>From individual to collective 3D cancer dissemination: roles of collagen concentration and TGF-β</article-title>
          <date>
            <year>2018</year>
          </date>
          <source>Sci. Rep</source>
          <volume>8</volume>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
